In Vivo and In Vitro Characteristics of Radiolabeled Vesamicol Analogs as the Vesicular Acetylcholine Transporter Imaging Agents

Contrast Media & Molecular Imaging
Kazuma Ogawa, Kazuhiro Shiba

Abstract

The vesicular acetylcholine transporter (VAChT), a presynaptic cholinergic neuron marker, is a potential internal molecular target for the development of an imaging agent for early diagnosis of neurodegenerative disorders with cognitive decline such as Alzheimer's disease (AD). Since vesamicol has been reported to bind to VAChT with high affinity, many vesamicol analogs have been studied as VAChT imaging agents for the diagnosis of cholinergic neurodeficit disorder. However, because many vesamicol analogs, as well as vesamicol, bound to sigma receptors (σ1 and σ2) besides VAChT, almost all the vesamicol analogs have been shown to be unsuitable for clinical trials. In this report, the relationships between the chemical structure and the biological characteristics of these developed vesamicol analogs were investigated, especially the in vitro binding profile and the in vivo regional brain accumulation.

References

Jan 1, 1991·Progress in Neurobiology·N J Woolf
Dec 1, 1990·Journal of Neuroscience Research·K J ReinikainenP J Riekkinen
Aug 1, 1990·Journal of Medicinal Chemistry·Y W JungD M Wieland
Jan 1, 1989·Progress in Brain Research·K Semba, H C Fibiger
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·B A Bahr, S M Parsons
Jul 1, 1984·Canadian Journal of Physiology and Pharmacology·P L McGeer
Aug 1, 1981·The Journal of Comparative Neurology·H KimuraE G McGeer
Apr 1, 1994·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·S M EfangeP H Evora
Jan 1, 1993·Progress in Brain Research·R QuirionP Gaudreau
Nov 1, 1993·Nuclear Medicine and Biology·M E Van DortD M Wieland
Feb 10, 1998·European Journal of Pharmacology·J K StaleyS M Efange
Apr 28, 2005·Neuroscience Letters·Nicolaas I BohnenSteven T DeKosky
Jan 26, 2006·Bioorganic & Medicinal Chemistry·Kazuhiro ShibaHirofumi Mori
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Hassan Pajouhesh, George R Lenz
Feb 23, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Y SunR-C Chen

❮ Previous
Next ❯

Citations

Sep 22, 2019·European Journal of Nuclear Medicine and Molecular Imaging·Stuart P McCluskeyOliver Howes
Jun 3, 2021·International Journal of Molecular Sciences·Rareş-Petru MoldovanWinnie Deuther-Conrad
Feb 6, 2020·Molecular Pharmaceutics·Anna SchildtJanine Doorduin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.